Evidence map›Paper›PMID 38236527›Full record

ArticleJournal of health monitoring2023

Research on Rare Diseases in Germany - Using small fish and super-resolution microscopy to track down a rare disease.

Nicole Endlich

Open access · greenAbstract read
In one paragraph

Article in Journal of health monitoring, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 73% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Nicole EndlichInstitute of Anatomy and Cell Biology, Greifswald University Medicine.
Universitätsmedizin Greifswald · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Focal segmental glomerulosclerosis (FSGS) is a rare disease, or damage to the filtering units of the kidney, the glomeruli, about of which there is only limited knowledge and few treatment options. The STOP-FSGS consortium has set itself the goal to expand our knowledge of this disease and develop new treatment options. Project: Through intensive research and the use of state-of-the-art techniques such as super-resolution microscopy, AI-based imaging and single-cell research, the consortium aims to gain a deeper understanding of the mechanisms of FSGS. This will allow the disease to be diagnosed more accurately and thus enable targeted and more effective treatment of patients. Another focus is on the search for drugs that slow down or even cure the disease. Results: By establishing a rapid animal model, i.e. zebrafish larva, potential substances/drugs were identified that can alleviate FSGS. Moreover, super-resolution microscopy was used to precisely quantify the structural changes in the kidney by determining the so-called 'filtration slit density' (FSD) and to identify a marker allowing a personalised prognosis and assessment of the course of the disease. Conclusions: The results obtained help to better recognise the progression of FSGS and to optimally adapt treatment in order to improve the quality of life of the afflicted individuals and avoid renal replacement therapies.

Indexed as

FOCAL SEGMENTAL GLOMERULOSCLEROSISMEDICATIONPERSONALISED DIAGNOSTICSPODOCYTESSUPERRESOLUTION MICROSCOPYZEBRAFISH

Identifiers

PMID38236527
PMCPMC10790414
OpenAlexW4390988524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.